Data/hora: 04/06/2024 01:59:44

Provedor de dados: 	56	
País: 	Brazil	
Título: 	Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension	
Autores: 	Wang,Dong; Lu,Jian-Guo; Wang,Qing; Du,Xi-Lin; Dong,Rui; Wang,Peng; Zhao,Lei; Jiang,Xue; Yuan,Li-Juan.	
Data: 	2012-03-01	
Ano: 	2012	
Palavras-chave: 	YKL-40; MMP-9; Splenomegaly; Fibrosis; Portal hypertension; Immunohistochemistry.	
Resumo: 	YKL-40 has been identified as a growth factor in connective tissue cells and also a migration factor in vascular smooth muscle cells. To a large extent, the increase of serum YKL-40 is attributed to liver fibrosis and asthma. However, the relationship of the expression and clinical/prognostic significance of YKL-40 to the splenomegaly of patients with portal hypertension is unclear. In the present study, the expression of YKL-40 was studied by immunohistochemistry in 48 splenomegaly tissue samples from patients with portal hypertension and in 14 normal spleen specimens. All specimens were quickly stored at -80°C after resection. Primary antibodies YKL-40 (1:150 dilution, rabbit polyclonal IgG) and MMP-9 (1:200 dilution, rabbit monoclonal IgG) and antirabbit immunoglobulins (HRP K4010) were used in this study. The relationship of clinicopathologic features with YKL-40 is presented. The expression of YKL-40 indicated by increased immunochemical reactivity was significantly up-regulated in splenomegaly tissues compared to normal spleen tissues. Overexpression of YKL-40 was found in 68.8% of splenomegaly tissues and was significantly associated with Child-Pugh classification (P = 0.000), free portal pressure (correlation coefficient = 0.499, P &lt; 0.01) and spleen fibrosis (correlation coefficient = 0.857, P &lt; 0.01). Further study showed a significant correlation between YKL-40 and MMP-9 (correlation coefficient = -0.839, P &lt; 0.01), indicating that YKL-40 might be an accelerator of spleen tissue remodeling by inhibiting the expression of MMP-9. In conclusion, YKL-40 is an important factor involved in the remodeling of spleen tissue of portal hypertension patients and can be used as a therapeutic target for splenomegaly.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000300013	
Editor: 	Associação Brasileira de Divulgação Científica	
Relação: 	10.1590/S0100-879X2012007500010	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Medical and Biological Research  v.45 n.3 2012	
Fonte: 	info:eu-repo/semantics/openAccess